AMLX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
49.7M
+8.7%
45.7M
+4.4%
43.8M
+19.6%
36.6M
+1.6%
36.0M
R&D
28.4M
+19.3%
23.8M
-13.9%
27.6M
+30.2%
21.2M
+6.8%
19.9M
SG&A
21.3M
-2.8%
21.9M
+35.6%
16.2M
+5.0%
15.4M
-4.8%
16.2M
Operating Income
-49658000
-8.7%
-45693000
-4.4%
-43779000
-19.6%
-36605000
-1.6%
-36027000
EBITDA
-49625000
-8.7%
-45650000
-4.5%
-43681000
-19.7%
-36497000
-1.6%
-35907000
Net Income
-45489000
-4.8%
-43423000
-5.2%
-41284000
-25.1%
-32999000
+4.0%
-34386000
EPS (Basic)
$-0.38
+2.6%
$-0.39
-5.4%
$-0.37
-23.3%
$-0.30
+18.9%
$-0.37
EPS (Diluted)
$-0.38
+2.6%
$-0.39
-5.4%
$-0.37
-23.3%
$-0.30
+18.9%
$-0.37
Shares (Diluted)
118.9M
+7.0%
111.2M
+0.6%
110.6M
+0.4%
110.1M
+18.0%
93.3M
Amylyx Pharmaceuticals (AMLX) — Financials